|
Match
|
Document |
Document Title |
|
|
8183208 |
Targeted delivery of drugs for the treatment of viral infections
Conjugates of transferrin or transcobalamin with anti-viral agents are useful in the treatment of viral infections. Suitable anti-viral agents include apoptosis inducing compounds, compounds which...
|
|
|
8173600 |
Caspase-2 inhibitors and their biological applications
The invention relates to selective new caspase-2 inhibitors that recognize caspase-2 and prevent and block its activity based on the following backbone: 2-Quinolinylcarbonyl-L-Valinyl-L-Aspartyl...
|
|
|
8173128 |
Methods and compositions for inducing apoptosis in cancer cells with an anti-DR5 antibody
Anti-DR5 antibody agonists, combined with apoptosis-inducing agents, synergistically induce apoptosis in cancer cells.
|
|
|
8163694 |
Method of treating diseases or abnormal conditions of periodontal or dental tissues with GDF5
The present invention concerns improved osteoinductive materials comprising matrix materials and morphogenetic proteins, wherein depending on the subject matter the proteins may be dimeric or...
|
|
|
8143222 |
Modular platform for targeted therapeutic delivery
Pharmaceutical compounds, pharmaceutical compositions and methods of treatment are disclosed, wherein a compound comprises a targeting moiety which, in free form, binds a cell receptor with a...
|
|
|
8129344 |
Method of reducing cell death by administering a Sfrp polypeptide
A purified paracrine factor of a mesenchymal stem cell, such as a Secreted frizzled related protein (Sfrp) is useful to reduce cell death an/or tissue injury associated with ischemic condtions.
|
|
|
8119601 |
Voltage dependent anion channel (VDAC1) compositions and methods of use thereof for regulating apoptosis
The present invention relates generally to the mitochondrial protein, voltage-dependent anion channel (VDAC)5 polynucleotides encoding same and variants thereof, as well as peptide fragments,...
|
|
|
8093217 |
Methods and compositions for inhibition of multi-drug resistance by hyaluronan oligomers
Pharmaceutical compositions and methods for sensitizing multi-drug resistant cancer or radiation resistant cancer cells to chemotherapeutic agents are provided. Compositions include ligands of...
|
|
|
8080517 |
Cell-permeable peptide inhibitors of the JNK signal transduction pathway
The present invention refers to protein kinase inhibitors and more specifically to inhibitors of the protein kinase c-Jun amino terminal kinase. Additionally, the present invention provides JNK...
|
|
|
8076096 |
Alteration of cell membrane with FasL
Methods and compositions are provided for the persistent modification of cell membranes with exogenous proteins so as to alter the function of the cell to achieve effects similar to those of gene...
|
|
|
8048850 |
Covalent conjugates between artemisinin-related endoperoxides and iron-carrying proteins and methods of use
In one aspect, the invention provides covalent conjugates between artemisinin-related endoperoxides and iron-carrying proteins. In some embodiments, the covalent conjugates comprise artelinate and...
|
|
|
8039437 |
Fn14/TRAIL fusion proteins
Fusion proteins which act on the TWEAK and TRAIL signaling axes are provided. The proteins are useful in the treatment or amelioration of autoimmune diseases, particularly multiple sclerosis, as...
|
|
|
8034779 |
Inhibitors of BCL-2
A purified polypeptide includes an amino acid sequence consisting of about 10 to 80 amino acids, the amino acid sequence having a sequence identity at least 90% homologous to a portion of SEQ ID...
|
|
|
8008261 |
Methods of reducing trail-induced apoptosis by trail isoforms
This document provides to methods and materials related to apoptosis. For example, methods and materials for modulating apoptosis are provided. In addition, methods and materials for treating a...
|
|
|
8008260 |
Methods of protecting against apoptosis using lipopeptides
The use of lipopeptides as inducers of NF-κB for the protection of mammals from the effects of apoptosis is described.
|
|
|
8003613 |
Methods and compositions for inducing apoptosis
The C-terminal domain of focal adhesion kinase (FAK-CD) was isolated using a Baculoviral system. Using phage display techniques, a phage encoding a 12 amino-acid peptide (peptide 35) and AV3 that...
|
|
|
7985735 |
Dimeric IAP inhibitors
Smac mimetics that inhibit IAPs.
|
|
|
7981421 |
Combinations of antibodies selective for DR5 and other therapeutic agents
An antibody of the invention interacts with human DR5 or with human DR4 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and...
|
|
|
7960346 |
Tumor cytotoxicity induced by modulators of the CXCR4 receptor
The present invention provides a means of selectively killing epithelial cell carcinomas by administering a CXCR4-specific sequence of the Gp120 protein or Nef proteins or the proteins themselves...
|
|
|
7960347 |
Matrix protein compositions for induction of apoptosis
Enamel matrix, enamel matrix derivatives and/or enamel matrix proteins or peptides may be used as therapeutic or prophylactic agents for inducing programmed cell death (apoptosis), in particular in...
|
|
|
7951779 |
Method of protecting cells against damage and pharmaceutical composition comprising leumorphin
The present invention relates to a method of protecting cells against damage caused at least in part by apoptosis, comprising administering to subjects a therapeutic dose of leumorphin having...
|
|
|
7897562 |
Apoptosis-inducing agent and method for inducing apoptosis
An object of the present invention is to provide a novel means for stably and surely inducing cell apoptosis using the c-myc gene as a target. The present invention relates to an apoptosis-inducing...
|
|
|
7884078 |
CPG15 compounds as insulin receptor and insulin-like growth factor receptor agonists
Disclosed herein are CPG15 and CPG15-2 compounds and inhibitors that act as agonists and antagonists of the insulin receptor and insulin-like growth factor receptors, and the use of such...
|
|
|
7871784 |
Methods and compositions relating to the regulation of apoptosis by MUC1 and BH3-containing proapoptotic proteins
This invention relates to regulation of cell signaling, cell growth, and more particularly to the regulation of cancer or immune cell growth. The invention provides methods of inhibiting...
|
|
|
7846894 |
Chinese hamster apoptosis-related genes
Provided is an isolated polypeptide comprising a Cricetulus griseus sequence capable of mediating apoptosis of a cell, the sequence being selected from a FAIM sequence shown as SEQ ID NO: 1; a FADD...
|
|
|
7785601 |
Methods of treating neurological conditions with hematopoietic growth factors
The present invention relates to a method of treating neurological conditions in a mammal by administering a hematopoietic growth factor such as granulocyte-colony stimulating factor (GCSF) and...
|
|
|
7781413 |
SEMA3B inhibits tumor growth and induces apoptosis in cancer cells
The present invention identifies the semaphorin polypeptide SEMA3B as a tumor suppressor. This molecule can inhibit tumor growth and induce apoptosis of tumor cells when produced internally in a...
|
|
|
7776818 |
Methods to treat T-cell disorders using TISF
T4 Immune Stimulating Factor (TISF) selectively induces aberrant T-cells to initiate apoptosis. TISF and peptides that are related to TISF (TISF peptides) are therefore useful for the treatment of...
|
|
|
7772177 |
BIR domain binding compounds
The present invention is directed towards an isomer, an enantiomer, a diastereoisomer, or a tautomer of a pyrrolidine compound represented by Formula I: in which the substituents R1, R1a, R2, R2a,...
|
|
|
7759091 |
Therapeutic agents comprising pro-apoptotic proteins
The present invention relates to targeted killing of a cell utilizing a chimeric polypeptide comprising a cell-specific targeting moiety and a signal transduction pathway factor. In a preferred...
|
|
|
7741288 |
Methods of screening of PP1-interacting polypeptides or proteins, peptides inhibiting PP1c binding to Bcl-2 proteins, Bcl-xL and Bcl-w, and uses thereof
The present invention relates to methods for identifying novel PP1-interacting polypeptides and proteins, compounds which are able to inhibit the binding of PP1c to certain factors naturally...
|
|
|
7737114 |
Didemnin analogs and fragments and methods of making and using them
The present invention relates to macrocyclic depsipeptides, including didemnin analogs and fragments thereof, which are useful as anti-cancer agents and for other purposes. The invention includes...
|
|
|
7737111 |
Peptides and related molecules that bind to TALL-1
The present invention concerns therapeutic agents that modulate the activity of TALL-1. In accordance with the present invention, modulators of TALL-1 may comprise an amino acid sequence Dz2Lz4...
|
|
|
7723300 |
Regulators of the non-genomic action of progesterone and methods of use
A progesterone regulator capable of modulating the non-genomic action of progesterone and methods of using the progesterone regulator are described. The progesterone regulator is useful for...
|
|
|
7718600 |
IAP binding compounds
Compounds that bind cellular IAPs (inhibitor of apoptosis proteins) are disclosed. The compounds are mimetics of the N-terminal tetrapeptide of IAP-binding proteins, such as Smac/DIABOLO, IIid,...
|
|
|
7700353 |
Compositions and methods for inducing apoptosis in tumor cells
A method is described for using an E-domain peptide for the induction of apoptosis in a cancer cells. In particular, the invention relates to methods for using a-type E-domain peptide from trout...
|
|
|
7696156 |
Human hemojuvelin (HJV) or dragon-like 1 (DL-1) polypeptides and variants and uses thereof
This invention features methods and compositions useful for treating and diagnosing diseases of the nervous system, retina, skin, muscle, joint, and cartilage using a Dragon family protein. Protein...
|
|
|
7655620 |
Use of one or more metal carriers to selectively kill mammalian cells
Compositions and methods for decreasing the viability of cells, particularly aberrant non-healthy cells, and most particularly cancer cells, are disclosed. The primary agent that causes cell death...
|
|
|
7651997 |
Deoxo-proline-containing tamandarin and didemnin analogs, dehydro-proline-containing tamandarin and didemnin analogs, and methods of making and using them
The present invention relates to tamandarin and didemnin analogs which have a deoxo-proline residue or a dehydro-proline residue in their structure. These analogs are useful as anti-cancer agents...
|
|
|
7618939 |
Compositions and methods to prevent cancer with cupredoxins
The present invention relates to compositions comprising peptides that may be variants, derivatives and structural equivalents of cupredoxins that inhibit the development of premalignant lesions in...
|
|
|
7601341 |
Vascular endothelial growth factor fusion constructs used to inhibit osteoclastogenesis
The 121-amino acid isoform of vascular endothelial growth factor (VEGF121) is linked by a flexible G4S tether to a cytotoxic molecule such as toxin gelonin or granzyme B and expressed as a soluble...
|
|
|
7588912 |
Compositions and methods for preventing and treating anthrax diseases
Compounds, methods for identifying compounds and methods for using compounds which modulate interaction of lethal factor and anthrolysin O in the treatment and prevention of anthrax diseases are...
|
|
|
7589058 |
Ghrelin analogs
The invention comprises peptidyl analogs that possess agonist or antagonist ghrelin activity, along with therapeutic and non-therapeutic uses thereof.
|
|
|
7582478 |
Cleaved serum response factor in cardiac diagnosis and therapy
The present invention is directed to the cleavage of serum response factor as it relates to cardiac disease. In specific embodiments, failing cardiac tissue is diagnosed in tissues comprising...
|
|
|
7524490 |
Clusterin-mediated inhibition of apoptosis via stromal bone marrow cell delivery to a cardiac site
Methods and compositions are disclosed for inhibiting, deterring or preventing apoptosis of cardiac myocytes, transplanted stem cells, vascular stem cells, and vascular smooth muscle cells by means...
|
|
|
7517857 |
Immune-modulating peptide
Disclosed are peptides having SEQ ID NOs: 1 to 24 that induce superoxide generation by human monocytes or neutrophils; that induce an intracellular calcium increase by human peripheral blood...
|
|
|
7514400 |
Synthetic mimics of mammalian cell surface receptors: method and compositions
The present invention relates to new synthetic receptors. More particularly, the present invention relates to the use of the synthetic receptors for delivering a protein, peptide, drug, prodrug,...
|
|
|
7511016 |
Annexins, derivatives thereof, and annexin-cys variants, as well as therapeutic and diagnostic uses thereof
The present invention provides methods and compositions for the treatment, diagnosis, and prevention of diseases, such as neoplastic diseases, neurodegenerative diseases, cardiovascular diseases,...
|
|
|
7507711 |
Peptide inhibitors of protein kinase C
PKC V5 isozyme-specific peptides are described. The sequences and compositions comprising the sequences are useful for treating disease states associated with the PKC isozyme from which they are...
|
|
|
7498305 |
Activated protein C variants with normal cytoprotective activity but reduced anticoagulant activity
Variants (mutants) of recombinant activated protein C (APC) or recombinant protein C (prodrug, capable of being converted to APC) that have substantial reductions in anticoagulant activity but that...
|